Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, ACC, FVT

BioLineRx to Report First Quarter 2021 Results on May 26, 2021


TEL AVIV, Israel, May 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2021 on Wednesday, May 26, 2021, before the US markets open.

The Company will host a conference call on Wednesday, May 26, 2021 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0610 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until May 28, 2021; please dial +1-888-295-2634 from the U.S. or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem-cell mobilization for autologous bone-marrow transplantation. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all rights to Motixafortide), and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events.

Contact:

Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
[email protected]

Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
[email protected]

SOURCE BioLineRx Ltd.


These press releases may also interest you

at 19:05
Building Information Modeling (BIM) Software Market size is set to grow by USD 9.68 billion from 2024-2028, Increasing need for management of large-scale projects to boost the market growth, Technavio
The global building information modeling (BIM) software market size is estimated to grow by USD 9.68 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 22.79% during the forecast period. Increasing need for...

at 18:15
Lithium-Sulfur Battery Market size is set to grow by USD 3.92 billion from 2024-2028, Harmful usage of lead batteries leads to higher adoption of Li-S batteries boost the market, Technavio
The global lithium-sulfur battery market size is estimated to grow by USD 3.92 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  44.97%  during the forecast period. Harmful usage of lead batteries leads to...

at 18:05
Flexible Packaging Market size is set to grow by USD 51.6 billion from 2024-2028, Rise in demand for pouch packaging solutions boost the market, Technavio
The global flexible packaging market size is estimated to grow by USD 51.6 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.97% during the forecast period. Rise in demand for pouch packaging solutions is...

at 18:00
21700 Lithium-Ion Battery Market size is set to grow by USD 6.54 billion from 2024-2028, Improved capacity and performance of lithium-ion battery to boost the market growth, Technavio
The global 21700 lithium-ion battery market size is estimated to grow by USD 6.54 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 21.22% during the forecast period. Improved capacity and performance of...

at 17:50
Breast Tissue Expander Market size is set to grow by USD 282.4 million from 2024-2028, Increasing prevalence of breast cancer boost the market, Technavio
The global breast tissue expander market size is estimated to grow by USD 282.4 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  6.78%  during the forecast period. Increasing prevalence of breast cancer is...

at 17:40
Smart Factory Market size is set to grow by USD 97.1 billion from 2024-2028, Increasing focus of vendors on setting up new smart factories to boost the market growth, Technavio
The global smart factory market size is estimated to grow by USD 97.1 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.87% during the forecast period. Increasing focus of vendors on setting up new smart...

More news about Science and technology...


News published on and distributed by: